Detalhe da pesquisa
1.
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.
Oncologist
; 2024 Mar 23.
Artigo
Inglês
| MEDLINE | ID: mdl-38520742
2.
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
Oncologist
; 2024 May 08.
Artigo
Inglês
| MEDLINE | ID: mdl-38716772
3.
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.
Oncologist
; 29(1): 75-83, 2024 Jan 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37548439
4.
HER2-positive breast cancer: cotargeting to overcome treatment resistance.
Curr Opin Oncol
; 35(6): 461-471, 2023 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37621172
5.
Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer.
Cancer Treat Res
; 188: 237-281, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-38175349
6.
Postneoadjuvant treatment for triple-negative breast cancer.
Curr Opin Oncol
; 34(6): 623-634, 2022 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35993306
7.
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046.
Invest New Drugs
; 40(5): 1133-1136, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35612671
8.
Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates.
Crit Rev Oncol Hematol
; 195: 104270, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38272150
9.
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting.
Cancers (Basel)
; 16(2)2024 Jan 09.
Artigo
Inglês
| MEDLINE | ID: mdl-38254772
10.
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer.
Cancer Treat Rev
; 123: 102669, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38141462
11.
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer.
Cancer Treat Rev
; 128: 102761, 2024 May 16.
Artigo
Inglês
| MEDLINE | ID: mdl-38772169
12.
The HER2-low revolution in breast oncology: steps forward and emerging challenges.
Ther Adv Med Oncol
; 15: 17588359231152842, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36844387
13.
Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer.
Expert Opin Pharmacother
; 24(7): 789-801, 2023 May.
Artigo
Inglês
| MEDLINE | ID: mdl-37029518
14.
A comprehensive update of hormone-related pharmacokinetic variations associated with breast cancer drugs.
Expert Opin Drug Metab Toxicol
; 19(7): 389-403, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37695692
15.
Future potential targets of antibody-drug conjugates in breast cancer.
Breast
; 69: 312-322, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-36996620
16.
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data.
Eur J Cancer
; 190: 112958, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37451181
17.
Variant allele frequency: a decision-making tool in precision oncology?
Trends Cancer
; 9(12): 1058-1068, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37704501
18.
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience.
Eur J Cancer
; 183: 79-89, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36801623
19.
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.
Eur J Cancer
; 190: 112944, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37437366
20.
Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
Cancer J
; 28(6): 436-445, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36383906